# EDGAR Filing Document

**Accession Number:** 0000318306
**File Stem:** 0001493152-23-009464
**Filing Date:** 2023-3
**Character Count:** 6198
**Document Hash:** daaafa8c182325119e4788c06727f324
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-009464.hdr.sgml**: 20230329

**ACCESSION NUMBER**: 0001493152-23-009464

**CONFORMED SUBMISSION TYPE**: 424B5

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230329

**DATE AS OF CHANGE**: 20230329

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ABEONA THERAPEUTICS INC.
- **CENTRAL INDEX KEY:** 0000318306
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 830221517
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 424B5
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-256850
- **FILM NUMBER:** 23775229

**BUSINESS ADDRESS:**
- **STREET 1:** 1330 AVENUE OF THE AMERICAS, 33RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019
- **BUSINESS PHONE:** 646-813-4701

**MAIL ADDRESS:**
- **STREET 1:** 1330 AVENUE OF THE AMERICAS, 33RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PLASMATECH BIOPHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20140922

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ACCESS PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 19960209

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CHEMEX PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 19920703

**Filed Pursuant to Rule 424(b)(5)<br> Registration No. 333-256850**

**PROSPECTUS SUPPLEMENT**

**(To Prospectus dated October 22, 2021, as supplemented by Prospectus Supplement No. 1 dated November 19, 2021, Prospectus Supplement No. 2 dated July 19, 2022 and Prospectus Supplement No. 3 dated October 12, 2022)**

**Up to $4,872,300**

**Common Stock**

This prospectus supplement amends and supplements the information in the prospectus, dated October 22, 2021 (the "Prospectus"), filed with the Securities and Exchange Commission as a part of our registration statement on Form S-3 (File No. 333-256850), as previously supplemented by Prospectus Supplement No. 1 dated November 19, 2021, Prospectus Supplement No. 2 dated July 19, 2022 and Prospectus Supplement No. 3 dated October 12, 2022, relating to the offer and sale of up to $150,000,000 of shares of our common stock, pursuant to the Open Market Sale Agreement<sup>SM</sup>, as amended (the "Sale Agreement"), we previously entered into with Jefferies LLC ("Jefferies"). This prospectus supplement should be read in conjunction with the Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prospectus and any future amendments or supplements thereto. Through March 29, 2023, we have sold 10,237,760 shares of our common stock for aggregate gross proceeds of approximately $39.1 million in accordance with the Sale Agreement under the Prospectus.

We are filing this prospectus supplement to amend the Prospectus because we are subject to General Instruction I.B.6. of Form S-3, which limits the amounts that we may sell under the registration statement of which this prospectus supplement and the Prospectus are a part. After giving effect to these limitations and the current public float of our common stock, and after giving effect to the terms of the Sale Agreement, we currently may offer and sell shares of our common stock having an aggregate offering price of up to $4,872,300 under the Sale Agreement. If our public float increases such that we may sell additional amounts under the Sale Agreement and the registration statement of which this prospectus supplement and the Prospectus are a part, we will file another prospectus supplement prior to making additional sales.

Our common stock is listed on the Nasdaq Capital Market under the symbol "ABEO." The aggregate market value of our common stock held by non-affiliates as of March 29, 2023 pursuant to General Instruction I.B.6 of Form S-3 is $54,546,886, which was calculated based on 16,681,005 shares of our common stock outstanding held by non-affiliates and at a price of $3.27 per share, the closing price of our common stock on March 8, 2023. As of the date hereof, we have sold an aggregate of $13,309,995 of securities pursuant to General Instruction I.B.6 of Form S-3 during the prior 12 calendar month period that ends on and includes the date hereof. As a result of the limitations of General Instruction I.B.6 of Form S-3, and in accordance with the terms of the Sales Agreement, we are registering the offer and sale of shares of our common stock having an aggregate offering price up to $4,872,300 from time to time through Jefferies. In addition, we have agreed to reimburse the Agent for fees and disbursements paid to its legal counsel, in an amount not to exceed $50,000, in connection with this prospectus supplement and, upon the occurrence of certain events specified in the Sale Agreement, up to $15,000 in connection with each such specified event. In accordance with FINRA Rule 5110, these reimbursed fees and expenses are deemed sales compensation for this offering.

**Investing in our securities involves significant risks. Please see "Risk Factors" beginning on page S-4 of the Prospectus and in the documents incorporated by reference into the Prospectus and in our most recent Annual Report on Form 10-K and in our most recent Quarterly Reports on Form 10-Q, and any amendments thereto, which are incorporated by reference into the Prospectus, and under similar headings in the other documents that are filed after the date hereof and incorporated by reference into this prospectus supplement and the Prospectus for a discussion of the factors you should carefully consider before deciding to purchase our common stock.**

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus, this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.**

**Jefferies LLC**

The date of this prospectus supplement is March 29, 2023